The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Alectinib and Lorlatinib for ALK-Rearranged Lung Cancer: Sequential Generation ALK Inhibitors

Modern ALK-targeted therapy for ALK fusion-positive NSCLC with first-line and resistance setting options

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Alectinib and Lorlatinib for ALK-Rearranged Lung Cancer: Sequential Generation ALK Inhibitors?

ALK (anaplastic lymphoma kinase) gene fusions create constitutively active oncogenic kinases driving lung adenocarcinoma in 3-7% of cases.

EML4-ALK is most common fusion partner with KIF5B-ALK and other variants occurring less frequently.

Alectinib is second-generation ALK inhibitor with potent ALK and ROS1 activity, no MET inhibition and excellent CNS penetration.

Lorlatinib is third-generation macrocyclic ALK/ROS1 inhibitor designed to overcome multiple resistance mutations including G1202R.

Sequential ALK inhibitor therapy enables prolonged disease control with median overall survival exceeding 6 years in registry studies.

Symptoms

Alectinib commonly causes constipation, fatigue, edema, myalgia and increased bilirubin requiring monitoring and supportive care.
Photosensitivity reactions with alectinib require sun protection counseling and education.
Lorlatinib can cause hyperlipidemia requiring statin therapy, weight gain, edema and rare cognitive effects.
Mood changes including depression, anxiety and irritability with lorlatinib require monitoring and intervention.
Pneumonitis is rare but serious adverse event with both agents requiring vigilant respiratory monitoring.

Risk Factors

Younger age and never-smoker status correlate with ALK fusion-positive lung adenocarcinoma prevalence.
Brain metastases are common in ALK-positive disease but respond well to alectinib and lorlatinib's CNS-active properties.
Compound resistance mutations after sequential TKIs may limit treatment options requiring innovative trial enrollment.
Lipid abnormalities at baseline may worsen with lorlatinib requiring monitoring and statin initiation.
Drug interactions through CYP3A4 metabolism require concomitant medication assessment for both agents.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Newly diagnosed metastatic NSCLC adenocarcinoma should undergo molecular testing including ALK rearrangement analysis.
  • ALK-positive disease progression on first-line therapy warrants next-generation TKI consideration with rebiopsy when feasible.
  • Brain metastasis development on ALK TKI may benefit from CNS-active agent transition or dose intensification.
  • Cognitive or mood changes with lorlatinib require evaluation and possible psychiatric consultation.
  • Significant lipid abnormalities, weight gain or edema with lorlatinib require monitoring and management.

Treatment Methods

01
Alectinib 600 mg twice daily continuous dosing represents preferred first-line therapy with food administration.
02
Lorlatinib 100 mg once daily after first or second-generation TKI failure with rebiopsy informing selection when possible.
03
Comprehensive lipid management with lorlatinib including baseline assessment, statin initiation and ongoing monitoring.
04
Brain MRI surveillance every 3-6 months given CNS metastasis predilection and response evaluation.
05
Multidisciplinary care including medical oncology, neuro-oncology, palliative care and psychiatric services when needed supports optimal outcomes through sequential ALK-targeted therapy strategies for this molecularly defined disease.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.